OncoMatch/Clinical Trials/NCT05506332
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Is NCT05506332 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Venetoclax and 6-mercaptopurine for acute myeloid leukemia, in relapse.
Treatment: Venetoclax · 6-mercaptopurine — Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Acute Myeloid Leukemia
Performance status
WHO 0–2
Prior therapy
Must have received: intensive chemotherapy (ara-c, anthracycline) — relapsed or refractory after at least one cycle
Relapsed after or refractory to at least one cycle of intensive chemotherapy (combination of ara-c/anthracyclin)
Must have received: hypomethylating agent — relapsed or refractory after at least four cycles
or four cycles of HMA (hypomethylating agents)
Cannot have received: ABT-199 (venetoclax) and purine analogue (venetoclax)
Exception: Patient may be prior exposed but not refractory to venetoclax. In case of previous therapy with venetoclax inclusion is only possible after discussion with the PI.
ABT-199 (venetoclax) and PA-naïve. Patient may be prior exposed but not refractory to venetoclax. In case of previous therapy with venetoclax inclusion is only possible after discussion with the PI.
Cannot have received: antitumoral agent
Exception: Use within less than 5 times the half-life of the agent prior to the screening bone marrow examination
Use of any antitumoral agent within less than 5 times the half-life of the agent prior to the screening bone marrow examination
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05506332 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior ABT-199 (venetoclax) and purine analogue, antitumoral agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages